Logo do repositório
 
Publicação

Dextran as an adjunct in carotid endarterectomy: a systematic review and meta-analysis

datacite.subject.sdg03:Saúde de Qualidade
datacite.subject.sdg09:Indústria, Inovação e Infraestruturas
datacite.subject.sdg04:Educação de Qualidade
dc.contributor.authorSilva-Vieira,Duarte
dc.contributor.authorPereira-Neves, António
dc.contributor.authorNzwalo, Hipólito
dc.contributor.authorMyrcha, Piotr
dc.contributor.authorNeves, João Rocha
dc.date.accessioned2026-03-16T11:23:00Z
dc.date.available2026-03-16T11:23:00Z
dc.date.issued2025-11
dc.description.abstractBackground: Carotid endarterectomy (CEA) is a widely used surgical procedure to prevent stroke in patients with carotid artery stenosis. Dextran, an antithrombotic agent with antihemostatic properties, has been proposed as an adjunctive therapy to reduce thromboembolic complications during CEA. However, its effectiveness and safety remain controversial. This systematic review and meta-analysis aim to assess the incidence of thromboembolic and hemorrhagic complications in patients undergoing CEA with dextran administration. Methods: A systematic search was conducted in MEDLINE, Scopus, and Web of Science for studies evaluating the postoperative effects of dextran in CEA patients. Random-effects metaanalysis was performed to estimate the pooled incidence of adverse events, and heterogeneity was assessed through meta-regression analysis. The quality of the included studies was evaluated using the National Heart, Lung, and Blood Institute Study Quality Assessment Tool for observational studies and the Cochrane Risk-of-Bias 2 tool for randomized controlled trials (RCTs). Results: Ten studies, including a total of 149,540 patients, met the inclusion criteria. Of these, 9 were observational cohort studies (6 retrospective and 3 prospective), while one was an RCT. The meta-analytical incidence of stroke following CEA with dextran was 0.7% at 30 days post operatively (95% confidence interval, 0.3e1.1%), with moderate heterogeneity (I2 ¼ 50.79%, P ¼ 0.002). Meta-regression analysis indicated that geographic region significantly contributed to heterogeneity (P ¼ 0.010), while other clinical covariates, such as diabetes, hypertension, and coronary artery disease, were not associated with significant variations in outcomes. Dextran was primarily administered selectively to high-risk patients, with variations in dosing protocols across studies. Conclusion: The use of dextran in CEA was associated with a low incidence of thromboembolic events. However, some heterogeneity among studies highlights the need for further large-scale RCTs to clarify its efficacy and safety. Given the potential risks of dextran, including hemorrhage and renal complications, individualized patient selection and standardized administration protocols are recommended.eng
dc.identifier.doi10.1016/j.avsg.2025.06.022
dc.identifier.issn0890-5096
dc.identifier.urihttp://hdl.handle.net/10400.1/28424
dc.language.isoeng
dc.peerreviewedyes
dc.publisherElsevier
dc.relation.ispartofAnnals of Vascular Surgery
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleDextran as an adjunct in carotid endarterectomy: a systematic review and meta-analysiseng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage259
oaire.citation.startPage246
oaire.citation.titleAnnals of Vascular Surgery
oaire.citation.volume120
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameNzwalo
person.givenNameHipólito
person.identifier337064
person.identifier.ciencia-id2C1F-E4F3-2C79
person.identifier.orcid0000-0002-1502-3534
person.identifier.ridAAG-3931-2020
person.identifier.scopus-author-id36057285600
relation.isAuthorOfPublication287f7d4e-5ad8-4794-b526-c61d32c00446
relation.isAuthorOfPublication.latestForDiscovery287f7d4e-5ad8-4794-b526-c61d32c00446

Ficheiros

Principais
A mostrar 1 - 1 de 1
A carregar...
Miniatura
Nome:
1-s2.0-S089050962500442X-main.pdf
Tamanho:
1.47 MB
Formato:
Adobe Portable Document Format
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
3.46 KB
Formato:
Item-specific license agreed upon to submission
Descrição: